Completed

Detailed Study of Clinical Manifestations in Muenke Syndrome (FGFR3-Related Craniosynostosis)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Congenital Abnormalities+21

+ Tarsal Coalition

+ Bone Diseases

Over 1 Months
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: March 2005
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 31, 2005

Actual date on which the first participant was enrolled.

Muenke Syndrome, a specific form of craniosynostosis, is a condition where a baby's skull bones fuse prematurely. This can lead to various health issues such as coronal suture craniosynostosis, developmental delay, deafness, and carpal and tarsal bone fusion. This study aims to deepen our understanding of Muenke Syndrome's clinical manifestations to improve early diagnosis and clinical management, including genetic counseling. The study focuses on individuals with Muenke Syndrome and plans to enroll approximately 10-20 probands, along with their family members each year, with a maximum enrollment of 200 probands. The study is observational and has three main parts. The first part involves detailed physical, developmental, neurologic, dental, ophthalmologic, otolaryngologic, audiologic, radiologic, and genetic/genomic studies at the NIH Clinical Center and Children's National Medical Center. The second part is a genetic/genomic study aiming to investigate factors that influence the severity and expression of the disease. The third part is a cognitive function, development, and hearing questionnaire that patients can complete online, via phone, or by mail. The primary outcome of this study is to enhance our understanding of the genetics and clinical characteristics of Muenke Syndrome.

Official TitleClinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)
NCT00106977
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

137 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 1 Months

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesTarsal CoalitionBone DiseasesBone Diseases, DevelopmentalCraniosynostosesDysostosesEar DiseasesFoot DeformitiesFoot Deformities, CongenitalHearing DisordersMusculoskeletal AbnormalitiesMusculoskeletal DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeurologic ManifestationsOtorhinolaryngologic DiseasesSensation DisordersSigns and SymptomsPathological Conditions, Signs and SymptomsSynostosisLimb Deformities, CongenitalCraniofacial AbnormalitiesHearing LossLower Extremity Deformities, Congenital

Criteria

7 inclusion criteria required to participate
Subjects who have had confirmation of a Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory. Our research team must receive a photocopy of the positive test result in order to enroll a patient in the study.

All races and genders are known to be at risk for Muenke syndrome. Nationality or place of origin is not a specific barrier to participation.

Family members (typically parents or siblings) of probands with Muenke syndrome are also eligible to participate.

Any at risk individual will be given the option of enrolling in the research study for FGFR3 testing. Those individuals who are found to carry the p.Pro250Arg mutation may benefit from interventions like hearing screening or speech evaluations that would alter their medical management.

Show More Criteria

2 exclusion criteria prevent from participating
Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent.

Individuals for whom the medical risks of travel and evaluation at NIH appear to outweigh the benefits of study participation may be excluded.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

Childrens National Medical Center

Washington D.C., United StatesOpen Childrens National Medical Center in Google Maps
Suspended

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, United States
Completed2 Study Centers